View Older Stories

Jan 8, 2026 04:07PM KalVista reports $49 million revenue for EKTERLY in 2025

Jan 7, 2026 06:30PM Needham says this stock is 2026 winner as oral HAE drug gains early traction

Jan 6, 2026 07:08AM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $32 at Needham

Dec 23, 2025 05:30PM Jefferies lists 5 biotech M&A candidates for 2026

Dec 22, 2025 06:00AM KalVista gets Japanese approval for oral hereditary angioedema treatment

Dec 18, 2025 06:24AM BofA: 'Top SMid Biotech Picks Argenx, KalVista, Ocular, and Vertex'

Dec 3, 2025 01:15PM TD Cowen Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Nov 19, 2025 04:23AM Kalvista Pharma's (KALV) Ekterly Launch Looks Strong - Citizens

Nov 13, 2025 04:31AM Kalvista Pharma's (KALV) Ekterley One of The Harder Launches to Track - Citizens

Nov 11, 2025 04:30AM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Citizens

Nov 11, 2025 12:44AM KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 4c

Nov 6, 2025 08:02AM KalVista presents patient satisfaction data for EKTERLY at ACAAI meeting

Oct 6, 2025 04:00PM KalVista presents data on oral hereditary angioedema treatment in Europe

Sep 19, 2025 07:00AM KalVista gets European approval for oral hereditary angioedema drug

Sep 12, 2025 04:06AM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $28 at Citizens JMP

Sep 11, 2025 02:52PM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $36 at BofA Securities

Sep 11, 2025 07:04AM KalVista Pharmaceuticals (KALV) Misses Q1 EPS by 16c

Sep 11, 2025 07:02AM KalVista reports $1.4M EKTERLY revenue in first quarter since approval

Jul 25, 2025 08:00AM KalVista gets positive EU opinion for hereditary angioedema drug

Jul 17, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Jul 16, 2025 04:17AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Jul 15, 2025 04:05PM KalVista wins UK approval for oral hereditary angioedema treatment

Jul 11, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Jul 10, 2025 10:29AM Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Jul 8, 2025 08:21AM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $27 at H.C. Wainwright

Jul 8, 2025 04:03AM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $27 at Citizens JMP

Jul 7, 2025 02:40PM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $20 at Leerink Partners

Jul 7, 2025 12:20PM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $37 at BofA Securities

Jul 7, 2025 09:48AM Stifel Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Jul 7, 2025 06:31AM FDA approves KalVista's (KALV) oral HAE treatment EKTERLY

Jun 26, 2025 07:02AM KalVista Pharmaceuticals (KALV) Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

Jun 24, 2025 03:50PM Stifel Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Jun 24, 2025 01:57PM KalVista Pharmaceuticals (KALV) falls after FDA chief said to have sought rejection of drug

Jun 16, 2025 07:28AM Stifel Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Jun 16, 2025 07:03AM KalVista Pharmaceuticals (KALV) Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat

Jun 16, 2025 04:19AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Jun 13, 2025 04:06PM KalVista Pharmaceuticals (KALV) Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat

Apr 23, 2025 04:20AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Apr 8, 2025 06:31AM KalVista Pharmaceuticals (KALV) Enters Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

Mar 26, 2025 06:57AM Stifel Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Mar 26, 2025 06:49AM Cantor Fitzgerald Reiterates Overweight Rating on Kalvista Pharmaceuticals Inc (KALV)

Mar 26, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Mar 25, 2025 07:02AM KalVista Pharmaceuticals (KALV) Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Mar 17, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

Mar 13, 2025 04:36AM

Mar 12, 2025 07:00AM KalVista Pharmaceuticals (KALV) Misses Q3 EPS by 5c

Mar 3, 2025 07:05AM KalVista Pharmaceuticals (KALV) Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Mar 3, 2025 04:46AM Citizens JMP Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Feb 18, 2025 04:15AM JMP Securities Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

Jan 31, 2025 05:11AM JMP Securities Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

View Older Stories